特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
251573

腎線維症 : パイプライン製品の分析

Kidney Fibrosis - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 174 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
腎線維症 : パイプライン製品の分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 174 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

腎臓の中で細胞外基質が蓄積されていくと、腎線維症を引き起こします。これは糸球体硬化症と尿細管間質性線維症が特徴的な進行性の疾患で、腎臓機能に対して有害作用を与えることもあります。 素因は、外傷、感染症、手術、環境要因、そして化学物質や放射線への被曝が挙げられます。 症候は、疼痛、排尿に関連した問題、吐き気と嘔吐などがあります。 薬物や腎臓移植で症状を管理します。

当レポートでは、腎線維症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

腎線維症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;企業別
  • パイプライン製品;大学/機関別
  • 企業で開発中の製品
  • 大学/機関で研究中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AbbVie Inc
  • Allergan Plc
  • Angion Biomedica Corp
  • Apollo Endosurgery Inc
  • BiOrion Technologies BV
  • Cellmid Ltd
  • Epigen Biosciences Inc
  • Evotec AG
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • Horizon Pharma Plc
  • Intercept Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • MorphoSys AG
  • Pharmaxis Ltd
  • ProMetic Life Sciences Inc
  • Regulus Therapeutics Inc
  • Sirnaomics Inc
  • Symic Biomedical Inc
  • Vascular Biogenics Ltd

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Kidney Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Kidney Fibrosis - Pipeline by AdAlta Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H1 2020
  • Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H1 2020
  • Kidney Fibrosis - Pipeline by Blade Therapeutics Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Cellmid Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Curacle Co Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Evotec SE, H1 2020
  • Kidney Fibrosis - Pipeline by Future Medicine Co Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Galapagos NV, H1 2020
  • Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2020
  • Kidney Fibrosis - Pipeline by GenKyoTex SA, H1 2020
  • Kidney Fibrosis - Pipeline by iBio Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2020
  • Kidney Fibrosis - Pipeline by Kadmon Corp LLC, H1 2020
  • Kidney Fibrosis - Pipeline by Liminal BioSciences Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Max Biopharma Inc, H1 2020
  • Kidney Fibrosis - Pipeline by MedPacto Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Mission Therapeutics Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by NB Health Laboratory Co Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Novo Nordisk AS, H1 2020
  • Kidney Fibrosis - Pipeline by Oasis Pharmaceuticals LLC, H1 2020
  • Kidney Fibrosis - Pipeline by Osteoneurogen Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Redx Pharma Plc, H1 2020
  • Kidney Fibrosis - Pipeline by Sanofi, H1 2020
  • Kidney Fibrosis - Pipeline by Scholar Rock Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Senolytic Therapeutics Inc, H1 2020
  • Kidney Fibrosis - Pipeline by TiumBio Co Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Transcenta Holding Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Vectus Biosystems Ltd, H1 2020
  • Kidney Fibrosis - Dormant Projects, H1 2020
  • Kidney Fibrosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Kidney Fibrosis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Kidney Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12131IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H1 2020, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 34 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Kidney Fibrosis - Overview
  • Kidney Fibrosis - Therapeutics Development
  • Kidney Fibrosis - Therapeutics Assessment
  • Kidney Fibrosis - Companies Involved in Therapeutics Development
  • Kidney Fibrosis - Drug Profiles
  • Kidney Fibrosis - Dormant Projects
  • Kidney Fibrosis - Discontinued Products
  • Kidney Fibrosis - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.